Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| INDV | 8-K | neutral | 3/10 | Indivior entered into a $175 million accelerated share repurchase agreement with Barclays as part of its existing $400 m | May 4, 2026 |
| AXSM | PRESS-RELEASE | mixed | 6/10 | Axsome reported Q1 2026 revenue of $191.2M (57% YoY growth, slight beat vs $190.7M consensus), but GAAP EPS of -$1.26 mi | May 4, 2026 |
| KRYS | PRESS-RELEASE | bullish | 6/10 | Krystal Biotech reported strong Q1 2026 results with VYJUVEK revenue up 32% YoY to $116.4M and diluted EPS of $1.83, up | May 4, 2026 |
| MCRB | PRESS-RELEASE | neutral | 3/10 | Seres Therapeutics presented preclinical data for SER-603, a next-generation live biotherapeutic for IBD, at DDW 2026. T | May 4, 2026 |
| AURA | 424B5 | bearish | 6/10 | Aura Biosciences filed a preliminary prospectus supplement for an underwritten public offering of common stock and pre-f | May 4, 2026 |
| CABA | 8-K | bearish | 7/10 | Cabaletta Bio priced a $150M underwritten offering of 51.7M shares at $2.90/share, representing ~51% dilution from the p | May 4, 2026 |
| CABA | 424B5 | bearish | 7/10 | Cabaletta Bio is selling 51,725,000 shares of common stock at $2.90 per share in a dilutive follow-on offering, raising | May 4, 2026 |
| RNTX | 424B5 | bearish | 8/10 | Rein Therapeutics is selling 50,000,000 shares (2.8x current outstanding) at $1.00 per share, a 26% discount to the last | May 4, 2026 |
| AURA | 8-K | bullish | 6/10 | Aura Biosciences announced a CEO transition: founder Elisabet de los Pinos steps down and Natalie Holles, an experienced | May 4, 2026 |
| APUS | 8-K | bearish | 7/10 | APUS filed an 8-K detailing a comprehensive settlement resolving shareholder disputes and a forbearance agreement with i | May 4, 2026 |
| ODTX | S-1/A | mixed | 6/10 | Odyssey Therapeutics, a clinical-stage biopharma focused on autoimmune/inflammatory diseases, filed a revised S-1/A for | May 4, 2026 |
| CABA | 8-K | neutral | 3/10 | Cabaletta Bio announced it will present new clinical and translational data from 4 refractory patients treated with rese | May 4, 2026 |
| DAWN | 15-12G | neutral | 5/10 | Day One Biopharmaceuticals filed Form 15 to terminate its SEC registration and suspend reporting obligations, effective | May 4, 2026 |
| CDTTW | EFFECT | bearish | 6/10 | CDT Equity Inc.'s shelf registration (S-3, File No. 333-295226) became effective on May 1, 2026, enabling selling stockh | May 4, 2026 |
| COCP | EFFECT | bearish | 7/10 | Cocrystal Pharma's $150M shelf registration (S-3) became effective on May 1, 2026, allowing the company to offer securit | May 4, 2026 |
| AURA | PRESS-RELEASE | bearish | 5/10 | Aura Biosciences announced an underwritten public offering of common stock and pre-funded warrants, with a 30-day underw | May 4, 2026 |
| AURA | PRESS-RELEASE | mixed | 5/10 | Aura Biosciences announced the appointment of Natalie Holles as CEO and President, succeeding founder Elisabet de los Pi | May 4, 2026 |
| SCLX | PRESS-RELEASE | neutral | 4/10 | Scilex announces payment date of May 26, 2026 for a dividend of Dream Bowl Meme Coin tokens at 5 tokens per share, distr | May 4, 2026 |
| NVS | COURT-RULING | bearish | 6/10 | The Texas Court of Appeals denied Novartis's petition for writ of mandamus seeking to dismiss a qui tam action brought b | May 4, 2026 |
| SYRE | CLUSTER | neutral | 2/10 | CEO and CMO sold a combined $1.85M in open-market sales at ~$69.50, representing 0.027% of Spyre's $6.9B market cap. The | May 1, 2026 |
| PHVS | CLUSTER | neutral | 2/10 | Three Pharvaris insiders sold a total of $118K in stock over a one-week window, with the Chief Medical Officer accountin | May 1, 2026 |
| NRIX | CLUSTER | neutral | 2/10 | Three C-suite insiders at Nurix Therapeutics (NRIX) sold a total of ~$184K in open-market shares over a 7-day window, a | May 1, 2026 |
| SPTX | 424B4 | bullish | 7/10 | Seaport Therapeutics completed its initial public offering of 14,160,000 shares at $18.00 per share, raising $254.9 mill | May 1, 2026 |
| LNAI | 8-K | mixed | 7/10 | Lunai Bioworks completed a triangular merger to acquire a multi-jurisdictional CNS patent portfolio from Oncotelic and P | May 1, 2026 |
| CVM | S-1/A | mixed | 6/10 | CEL-SCI filed Amendment No. 1 to its S-1 for a best-efforts offering of up to 4,885,993 shares at $3.07/share, with net | May 1, 2026 |
| NAII | 8-K | neutral | 4/10 | CFO Michael E. Fortin resigned effective May 15, 2026 to join another company. President Kenneth E. Wolf, a former CFO, | May 1, 2026 |
| ISPC | 8-K | neutral | 3/10 | iSpecimen Inc. filed a Fifth Amended and Restated Certificate of Incorporation effective April 29, 2026, effecting a 1-f | May 1, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | Three UTHR insiders (CEO, CFO, and a director) sold a total of ~$3.77M in open-market shares over a one-week period, rep | May 1, 2026 |
| HOWL | 144 | neutral | 2/10 | MPM Asset Management Investors BV2014 LLC, a venture capital affiliate, filed a Form 144 indicating intent to sell 12,51 | May 1, 2026 |
| HOWL | 144 | neutral | 4/10 | Two major institutional holders, MPM BioVentures 2014 (B), L.P. and UBS Oncology Impact Fund L.P., filed Form 144 notice | May 1, 2026 |